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Abstract: The prevalence of obesity and dyslipidemia has increased worldwide. The role of trace
elements in the pathogenesis of these conditions is not well understood. This study examines the
relationship between dietary zinc (Zn) intake and plasma concentrations of Zn, copper (Cu) and iron
(Fe) with lipid profile indicators, fatty acid composition in plasma phospholipids and desaturase
enzyme activities in a dyslipidemic population. The role of the newly proposed biomarker of Zn status,
the linoleic:dihomo-gama-linolenic acid (LA:DGLA) ratio, in predicting Zn status of dyslipidemic
subjects has been explored. The study included 27 dyslipidemic adults, 39–72 years old. Trace
elements were determined using atomic absorption spectrometry and fatty acid composition by a
liquid gas chromatography. Desaturase activities were calculated from product-precursor fatty acid
ratios. Dietary data were obtained using 24 h recall questionnaires. Insufficient dietary intake of Zn,
low plasma Zn concentrations and an altered Cu:Zn ratio is related to modified fatty acid profile in
subjects with dyslipidemia. Plasma Zn status was associated with obesity. There was no correlation
between dietary Zn intake and plasma Zn status. The LA:DGLA ratio was inversely linked to dietary
Zn intake. Cu, in addition to Zn, may directly or indirectly, affect the activity of desaturase enzymes.
Keywords: Zn deficiency; Zn status; fatty acids; dyslipidemia; desaturases; dietary Zn intake
1. Introduction
The number of people affected by obesity and dyslipidemia has increased significantly during the
last two decades, largely attributed to the changes in dietary and lifestyle habits. Sixty-five percent
of the world’s population live in countries where overweight and obesity harm more people than
malnutrition [1]. According to the World Health organization (WHO) the worldwide obesity rates have
nearly tripled since 1975 [1]. In addition, the incidence of obesity related diseases (i.e., hypertension,
dyslipidemia, metabolic syndrome) also increases [1,2]. Dyslipidemia is described as the presence
of non-optimal blood lipids levels. People with dyslipidemia have either increased concentrations
of triglycerides or low-density lipoprotein cholesterol (LDL-C), or decreased levels of high-density
lipoprotein cholesterol (HDL-C) [3,4]. Raised cholesterol levels cause on average 2.6 million deaths and
29.7 million disability adjusted life years (DALYS) [1]. Dyslipidemia is one of the major contributors to
atherosclerotic and ischemic heart disease [1,5,6]. In 2008, the prevalence of raised blood lipid levels
among adults globally was 39% [1] and WHO identified that the occurrence was the highest in the
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region of Europe (54% for both sexes). Successful treatment of dyslipidemia significantly reduces
morbidity and mortality from cardiovascular diseases [7]. Basically 10% reduction in serum lipid levels
has been reported to result in a 50% reduction in heart disease within 5 years [1].
Trace elements have crucial roles in metabolism, growth, immunological and neurological
functions [8–10]. Zinc (Zn) is required for an adequate activity of more than 300 enzymes involved
in protein synthesis, fatty acid metabolism, reproduction and oxidative clearance [11]. Iron (Fe) is
needed for proper oxygen transport, while copper (Cu) is important for the oxido-reduction and
detoxification and is involved in growth, development of cellular elements of arterial walls, lipoprotein
metabolism and immune function [9,12,13]. The concentrations of serum/plasma minerals Zn, Cu and
Fe are associated with the development of chronic diseases [10,14,15]. Deficiency in microelements
leads to an increase in fat deposition and obesity [16]. Hypoferremia is often seen in people suffering
from hypertension and plasma Zn concentrations have been directly correlated with total cholesterol
and LDL-C levels [15,17]. Zn, Cu and Fe plasma levels are related to the extent of myocardial
damage [18]. Epidemiological studies show a direct correlation between low plasma Zn and Fe
concentrations and increased risk of cardiovascular diseases [19]. Elevated plasma levels of Cu were
reported in patients with coronary artery disease [20]. Although deficiencies of trace elements may
alter metabolism of lipids and lipoproteins, the mechanism of their action is not yet completely
understood. The fatty acid (FA) composition in serum phospholipids remains a reliable biomarker
of long-term fat intake [21] and it can predict the development of metabolic and cardiovascular
diseases [22]. It shows the endogenous FA metabolism, regulated by desaturase enzymes (∆5, ∆6 and
∆9). Desaturase enzymes convert dietary FAs to long-chain omega 3 and omega 6-polyunsaturated
fatty acids (PUFAs), the latter with demonstrated role in the prevention of dyslipidemia and metabolic
syndrome [23,24]. Serum FA composition also predicts long-term development of dyslipidemia and
metabolic syndrome [25–27]. Furthermore, alterations in desaturase activities were seen in subjects
who are obese and insulin resistant [28,29]. Trace elements have a role in FA metabolism. Zn is
a cofactor for desaturases and elongases in endogenous FA synthesis [30–35], so the alterations in
plasma levels of Zn possibly influence the activities of these enzymes and consequently the regulation
of FA metabolism. Serum concentrations of Zn and Fe correlated with serum PUFA concentrations
and activities of certain desaturases [36–38]. However, the role of micronutrients in dyslipidemia
warrants further research. Linoleic/dihomo-gama-linolenic acid (LA:DGLA) ratio is linked with dietary
Zn intakes and this ratio has been proposed as a novel biomarker of Zn status in both animals and
humans [32,33,35,39]. The predictive potential of this ratio has not been investigated in dyslipidemic
subjects so far. The primary aim of this study was to examine the relationship between plasma
concentrations of Zn, Cu, and Fe with long-chain individual FAs, FAs belonging to de novo lipogenesis
pathway and estimated desaturase activities in a group of dyslipidemic adults. The relationship of the
microelements with anthropometric and lipid profile parameters was assessed. The LA:DGLA ratio,
an emerging biomarker of Zn status, has been additionally examined for potential correlations with
clinical parameters. Finally, the contribution of particular food groups to the relationships between
trace elements and fat metabolism was evaluated.
2. Materials and Methods
2.1. Study Population
This cross-sectional study is the part of a larger nutritional intervention study registered
as NCT03227497 (ClinicalTrials.gov). Eligible subjects were non-smoking adults at moderate
cardiovascular risk, the latter defined as the presence of at least one of the following: increased
body mass index (BMI = 25–30 kg/m2), central obesity (waist circumference ≥ 80 cm for women and
≥94 cm for men), and high normal blood pressure (systolic/diastolic blood pressure (SBP/DBP) > 120/80,
≤139/89 mm Hg). Dyslipidemia was defined according to the guideline of the US National Cholesterol
Education Program Adult Treatment Panel III (NCEP-ATP III) [7,40]. The exclusion criteria were
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the presence of chronic disease, self-reported allergy to any type of nuts, pregnancy, lactation, blood
donation 16 weeks before the start of the study and a parallel participation in another clinical trial.
Recruitment of the subjects was performed via newspaper advertisement or word of mouth.
For the purposes of the current sub-study, we selected subjects with disturbed levels of serum lipids, as
seen in either: elevated serum total cholesterol (≥5.2 mmol/L), and/or elevated low-density lipoprotein
cholesterol (LDL-C ≥ 3.4 mmol/L) and/or elevated serum triacylglycerides (TG ≥ 1.7 mmol/L) and/or
decreased high-density lipoprotein cholesterol (HDL-C ≤ 1.04 mmol/L and 1.29 for men and women,
respectively). Finally, we were left with 27 dyslipidemic subjects of both genders, who were examined in
the current study to assess the relationship between micronutrient intake and status with fat metabolism.
2.2. Ethical Considerations
All subjects went through the informed consent process, both verbal and written. The study
protocol was approved by the Institute for Medical Research, University of Belgrade, Belgrade, Serbia,
Ethics Committee Approval, No: EO120/2017. The study was conducted in agreement with the ethical
guidelines on biomedical research on human subjects of The Code of Ethics of the World Medical
Association’s Declaration of Helsinki (1964) and its further amendments [41]. This study forms a part
of the randomized clinical trial registered as NCT03227497 (ClinicalTrials.gov).
2.3. Blood Samples Collection and Analysis
Blood samples were collected after an overnight fast (>10 h fasting) between 7–8 a.m. by
venepuncture of the antecubital vein. Tubes with ethylenediaminetetraacetic acid as anticoagulant
were used, and all of them were free of trace elements. Lipid status and concentration of glucose, along
with other routine biochemical parameters were determined from serum samples on the same day they
were collected. For this purpose, a clinical chemistry analyzer Cobas c111 was used (Roche Diagnostics,
Basel, Switzerland) and Roche Diagnostics’ kits according to the manufacturer’s instructions.
2.4. Anthropometric Measurements
Anthropometric variables, height and weight, were measured to the nearest 0.1 cm and 0.1 kg,
respectively. The weight and percent of fat mass in the body composition of participants were measured
using a TANITA UM072 balance (TANITA Health Equipment H.K. LTD, Hong Kong, China). The BMI
was calculated as the ratio of weight (kg) to height squared (m2). BMI was used to assess the prevalence
of overweight (25–29.9 kg/m2) and obesity (≥30 kg/m2) according to WHO criteria [1].
2.5. Assessment of Dietary Zn Intake
Dietary intake assessment was based on two 24 h recalls collected for non-consecutive days,
one working day and one weekend day, to capture the intra-individual food consumption variability.
Nutritional evaluation was performed during pre-scheduled participants’ visit to the study center
within in-depth interviews conducted by trained researchers. Recalls were administered according
to multiple-pass approach with standardized protocol, interview structure, and probing questions.
To facilitate the evaluation of food servings and improve accuracy of reporting, participants were
prompted with validated two-dimensional portion size estimation aid i.e., booklet comprising
photograph-series illustrating a range of reference portions for 135 items (both simple foods and
recipes) commonly consumed in the Balkan region [42]. In conjunction with the photographic atlas,
household measures, package/labelling data, the standard serving size information and natural units
were used to quantify the amount of food consumed.
Dietary questionnaires were coded and analyzed using Diet Assess & Plan, an advanced nutritional
software tool, evaluated by European Food Safety Authority (EFSA) and successfully used in various
national/regional surveys and international projects [43,44]. The consumption data was converted to
nutrient intake estimates according to the Serbian Food Composition Database, compiled and managed
in accordance with the international guidelines and embedded in the European Food Information
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Resource AISBL (EuroFIR AISBL) platform [45]. Nutrient intake calculation was performed by
multiplying the estimated gram weight of the consumed food with the nutrient contents per gram
from the food composition table. The average daily intakes of energy, macronutrients, trace elements,
FAs, and the main food groups were derived from a mean of two administrations of the questionnaire.
2.6. Fatty Acid Determination and Estimation of Desaturase Activity
Fatty acid concentrations were determined by gas chromatography (GC). By use of
chloroform-methanol mixture (2:1), total plasma lipids were extracted according to method of
Folch et al. [46]. To prevent lipid peroxidation, 2,6-di-tert-butyl-4-methylphenol (10 mg/100 mL) were
added to the mixture of solvents. Further on, phospholipids were separated from total lipids on silica
thin-layer chromatography plate, on a mixture of petroleum ether, diethyl ether, and glacial acetic
acid (87:12:1) used as a solvent system. Following the previously described procedure [47] with slight
modifications [48] FA methyl-esters were further obtained by direct trans-methylation. Obtained FA
methyl-esters were analyzed by gas chromatography on Shimadzu chromatograph GC 2014, Tokyo,
Japan equipped with a flame ionization detector and a Rtx 2330 fused silica gel capillary column
(60 m × 0.25 mm id × 0.2 µm film thickness) (Restek Co., Bellefonte, PA, USA) according to method by
Veselinovic et al. [48]. For the purposes of current study oleic acid (18:1 n-9), alpha-linolenic acid (LNA,
18:3 n-3), linoleic acid (LA, 18:2 n-6), dihomo-γ-linolenic acid (DGLA, 20:3 n-6), arachidonic acid (ARA,
20:4 n-6), adrenic acid (AA, 22:4 n-6), eicosapentaenoic acid (EPA, 20:5 n-3), docosapentaenoic acid (DPA,
22:5 n-3), and docosahexaenoic acid (DHA, 22:6 n-3) were identified. The peak retention times were
compared with certified calibration mixtures (PUFA-2, Supelco, Bellefonte, PA, USA, and 37 FAMEs mix,
Sigma Chemical Co., St. Louis, MO, USA). The amounts of individual FA are presented as the relative
percentage of the total (100%) FA pool. The desaturase activities were estimated as precursor-to-product
ratios of individual FAs as follows: the ratio AA/DGLA (20:4 n-6/20:3 n-6) for delta 5 desaturase, GLA/AA
(20:3 n-6/18:2 n-6) for delta 6 desaturase and 16:1 n-7/16:0 ratio for delta 9 desaturase [49].
2.7. Mineral Analysis
The analysis of plasma mineral concentrations was conducted using flame atomic absorption
spectrometry on a Varian SpectrAA-10 (Varian, Inc., Mulgrave, Victoria, Australia) according to
the method described by Jian Xin [50]. The reference range used for plasma Zn concentration was
0.7–1.5 mg/L; 0.5–1.5 mg/L was used for Fe and 0.7–1.4 mg/L for Cu [51–53]. To verify the accuracy of the
method, two control serums with certified concentrations of zinc, cooper and iron, (ClinChek-Control,
Recipe Chemical + Instruments GmbH; catalogue number 8882) were analyzed. Method performance
was monitored by analysis of the same control serums within each of the series. The obtained results
agreed with the certified values.
2.8. Statistical Analysis
The normality of the data was assessed with the Shapiro–Wilk test. Normally distributed data are
presented as mean (standard deviation) (SD) and non-normally scattered as median [interquartile range].
The variability in the baseline parameters was determined depending on the plasma Zn status, stratified
according to Zn tertiles. The total number of participants when divided according to tertiles was 23.
The difference between the tertiles in the selected variables was explored with one-way analysis of
variance test for normally distributed data, and with Kruskal Wallis test for non-normally distributed
data. To explore potential relationships between the study outcomes, the correlation analyses
were employed. For normally distributed data, Pearson’s correlation tests were used, while for
non-normally distributed data the corresponding non-parametric-Spearman’s correlation test was
employed. To explore potential confounding effects, partial correlation tests were used, with addition
of the following variables: age, gender, plasma Zn status. All analysis was performed in SPSS version
23.0 (BM Corp., Armonk, NY, USA), with a significance threshold set at 0.05. Graphical presentations
were generated in RStudio (2019) (Version 1.2.1335, Boston, MA, USA) [54].
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3. Results
3.1. Baseline Characteristics of Study Participants
Table 1 illustrates the baseline characteristics of study participants based on the tertiles of plasma
Zn concentrations. The mean age of the participants was 56 with values ranging from 39–72. Forty-eight
percent of this study population was overweight and 22% obese. Values for BMI fluctuated from 18.4
to 39.6, with a mean value of 28.2 kg/m2. Fifty-two percent of people had a waist:hip ratio above 0.86.
The percentage of study subjects with high total cholesterol and high LDL-C was 88%, while 30% of the
complete sample was with low levels of HDL-C. Increased level of TG, in addition to high LDL-C and
low HDL-C, was seen in 18.5% of participants. The mean fasting blood glucose (FPG) was 5.17nmol/L,
with 25% of people with glucose levels above the reference value of 5.84nmol/L. Fifty-seven percent of
subjects had elevated blood pressure (reference range 130/80).








(n = 8) p-Value
Clinical Parameters
Age, Years 57.00 [16.00] 59.50 [15.00] 63.00 [24.00] 53.00 [14.00] p = 0.781
Weight, Kg 77.50 [31.30] 68.65 [18.37] 76.4 [22.70] 95.90 [21.10] p = 0.001
BMI, Kg/M2 27.10 [8.30] 24.85 [8.97] 26.60 [3.80] 34.10 [9.82] p = 0.009
Plasma Zn, Mg/L 0.75 [0.14] 0.64 [0.09] 0.75 [0.05] 0.86 [0.08] p < 0.001
Plasma Fe, Mg/L 0.85 [0.65] 0.82 [0.23] 1.10 [0.91] 0.90 [0.76] p = 0.328
Plasma Cu, Mg/L 0.98 [0.16] 1.01 [0.06] 0.94 [0.11] 0.95 [0.18] p = 0.289
Cu:Zn 1.27 [0.39] 1.60 [0.36] 1.26 [0.10] 1.05 [0.31] p < 0.001
Total Cholesterol, Mmol/L 5.87 [1.26] 5.87 [0.67] 6.65 [1.29] 5.95 [0.96] p = 0.383
HDL-C, Mmol/L 1.41 [0.64] 1.69 [0.35] 1.28 [0.60] 1.22 [0.59] p = 0.318
LDL-C, Mmol/L 3.95 [0.79] 3.59 [0.60] 4.33 [1.00] 3.83 [0.58] p = 0.076
TG, Mmol/L 1.20 [0.69] 1.00 [0.33] 1.56 [0.49] 1.37 [0.77] p = 0.928
FPG, Nmol/L 5.17 [0.98] 4.96 [0.57] 5.76 [1.11] 5.53 [1.16] p = 0.166
Systolic BP, MmHg 131.00 [32.00] 137.00 [51.75] 120.00 [29.00] 136.50 [13.00] p = 0.295
Diastolic BP, MmHg 81.00 [22.00] 76.50 [17.75] 70.00 [19.00] 90.50 [14.50] p = 0.075
Fatty Acids in Plasma Phospholipids%
18:1 n-9 8.11 [1.89] 8.04 [1.27] 8.12 [2.40] 8.02 [1.59] p = 0.951
18:2 n-6 24.01 [5.09] 26.62 [5.51] 25.69 [6.79] 21.99 [4.10] p = 0.385
18:3 n-3 0.08 [0.068] 0.11 [0.05] 0.07 [0.05] 0.08 [0.08] p = 0.214
20:3 n-6 2.83 [1.28] 2.71 [1.17] 2.83 [1.29] 2.71 [1.32] p = 0.958
20:4 n-6 11.67 [2.84] 10.86 [4.90] 11.58 [2.72] 12.27 [1.03] p = 0.330
20:5 n-3 0.27 [0.21] 0.27 [0.57] 0.23 [0.09] 0.42 [0.16] p = 0.239
22:4 n-6 0.36 [0.17] 0.33 [0.22] 0.40 [0.16] 0.37 [0.15] p = 0.775
22:5 n-3 0.55 [0.15] 0.27 [0.57] 0.50 [0.16] 0.56 [0.19] p = 0.436
22:6 n-3 2.49 [1.42] 2.44 [1.95] 2.40 [0.17] 3.32 [1.33] p = 0.403
∆5-Desaturase 3.68 [1.80] 3.47 [0.61] 3.82 [1.53] 4.52 [2.88] p = 0.406
∆6-Desaturase 0.009 [0.003] 0.007 [0.005] 0.009 [0.003] 0.009 [0.003] p = 0.866
LA: DGLA 8.81 [3.85] 9.45 [6.18] 8.93 [3.94] 8.47 [2.94] p = 0.856
∆9-Desaturase 0.14 [0.01] 0.013 [0.004] 0.014 [0.010] 0.012 [0.005] p = 0.145
Data are presented as median [interquartile range] in complete sample and according to the tertiles of plasma zinc
levels. Bolded p-values represent the results of one-way ANOVA or Kruskal Wallis test on significant differences
between the Zn tertiles. Abbreviations: BMI—body mass index; HDL-C—high-density lipoprotein cholesterol;
LDL-C—low-density lipoprotein cholesterol; Body Fat%-body fat percentage; TG–triglycerides; FPG-fasting plasma
glucose; BP-blood pressure; LA: DGLA-linolenic acid/dihomo-gama-linolenic acid ratio.
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The average plasma Zn concentration was 0.75 ± 0.1 mg/L with 26% of participants having plasma
Zn concentrations below 0.7 mg/L. More than 50% of study subjects were with plasma Zn levels
below 0.75 mg/L, with the highest concentration of 1.03 mg/L being measured. The average Cu:Zn
ratio was 1.3. The levels of Cu and Fe were within the recommended reference ranges for healthy
people. The percentage of individual FAs and desaturase enzyme activities are presented in Table 1.
The plasma levels of Zn increased with higher weight and BMI. No differences between the groups
were seen for plasma concentrations of either Fe or Cu. There was a statistically significant difference
in the Cu:Zn ratio between the tertile groups, with the highest ratio observed in the 1st Zn tertile.
No statistically relevant relations were shown between the groups for any of the lipid profile indicators.
Concentrations of the individual FAs did not differ between the Zn formed groups (p > 0.05).
3.2. Associations between Plasma Zn, Fe, and Cu Status with Anthropometrical and Biochemical Measures
There was a direct correlation between Zn and BMI, and a significant inverse relation between the
Cu:Zn ratio and BMI. The relationships remained in the age and gender-adjusted model: Zn correlated
directly (r = 0.536, p = 0.02), while Cu:Zn ratio inversely (r = −0.488, p = 0.02) with BMI. There was an
inverse relationship between the Cu:Zn ratio with Cho/HDL, LDL/HDL and non-HDL/HDL (Table 2).
Fe and Cu were not correlated with any of the biochemical parameters measured in this study (Table 2).
No statistically significant correlations were observed between the plasma concentrations of
different minerals (p > 0.05). There is no statistically relevant association between the Fe status and
anthropometry parameters except for the inverse correlation with the percentage of body fat (Table 2).
3.3. The Link between the Plasma Zn, Cu, and Fe Status with Total Phospholipid FA Composition and
Desaturase Enzyme Activities
There were no significant correlations between the plasma Zn and any of the FAs measured in this
study. Cu was directly related to oleic acid (18:1 n-9) and alpha-linolenic acid (ALA, C18:3 n-3). Plasma
Fe correlated directly with oleic acid, while Cu:Zn ratio was directly associated with alpha-linolenic
acid (Table 3).
No statistically significant relationships were seen among the plasma status of either Zn or Fe
with any of the desaturases. There was an inverse correlation trend between the LA:DGLA and
Zn and Fe status and a direct relationship between the Cu and LA:DGLA ratio, without reaching
statistical significance.
3.4. The Link between the Status of the Individual FAs with Certain Components of Dyslipidemic Status
(Anthropometrical and Biochemical Parameters)
The linoleic acid correlated inversely, while arachidonic acid was directly linked to BMI (Table 4).
No other significant links between the status of individual FAs and anthropometry indicators were
observed. Similarly, no correlations were seen between the biochemistry related parameters and FAs,
except for the direct correlations of oleic acid (C18:1 n-9) with total cholesterol and HDL-C (Table 4),
and for the direct relationship between dihomo-gamma-linolenic acid (DGLA; C20:3 n6) and TGs.
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Table 2. Correlations between plasma levels of trace elements (Zn, Fe, Cu) and Cu:Zn ratio with anthropometrical and biochemical parameters in study subjects.
















































































Abbreviations: Body Fat%-body fat percentage; FPG-fasting plasma glucose; TG–triglycerides; Cho/HDL–total cholesterol/HDL-C ratio.
Table 3. Correlations of plasma concentrations of trace elements (Zn, Fe, Cu) and Cu:Zn ratio with plasma fatty acids and estimated desaturase activity in study subjects.
18:1 n-9 18:2 n-6 18:3 n-3 20:3 n-6 20:4 n-6 20:5 n-3 22:4 n-6 22:5 n-3 22:6 n-3 LA: DGLA ∆5-Desaturase ∆6-Desaturase




























































































Abbreviations: LA: DGLA-linolenic acid/dihomo-gama-linolenic acid ratio.
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Table 4. Correlations between individual plasma fatty acids with anthropometrical and biochemical
parameters in study subjects.
BMI Body Fat% TG Cholesterol LDL-C HDL-C



































































































Abbreviations: Body Fat%-body fat percentage; TG–triglycerides.
3.5. Correlations between LA:DGLA Ratio and Estimated Desaturase Activities with FAs, Anthropometrical,
and Biochemical Indices
The LA:DGLA ratio was inversely linked to BMI (Table 5). Predicted activities of ∆5 and ∆9
desaturases were not linked to any anthropometry measure, while ∆6 desaturases was directly related
to BMI. LA:DGLA was inversely associated with TG, Cho/HDL ratio and non-HDL/HDL. ∆5 desaturase
was inversely related to TG levels (Table 5). ∆6 and ∆9 desaturases have not been linked to any of the
biochemistry related parameters assessed. ∆5 desaturase was directly related with arachidonic and
docosahexaenoic and inversely with LA and DGLA (Table 5).
The linoleic acid was directly associated with the LA:DGLA ratio and inversely linked to all
desaturases. The relations among FAs and projected desaturase activities were not affected by plasma
Zn concentrations upon addition to the partial correlation models (data not presented).
Table 5. Correlations between LA:DGLA ratio and desaturase activities with the status of individual
plasma fatty acids, BMI, and biochemical parameters in study subjects.
18:2 n-6 20:3 n-6 20:4 n-6 22:6 n-3 BMI TG Cho/HDL LDL/HDL Non-HDL/HDL




































































Abbreviations: TG–triglycerides; Cho/HDL–total cholesterol/HDL-C ratio.
3.6. Dietary Zn Intake of Participants
The average daily dietary Zn intake was 7.42 ± 1.82 mg/day with about 65% of study participants
having intakes below the recommendations (8–11 mg/day) [55]. Grains and grain products (white
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and wholemeal bread) were the most significant sources of dietary Zn, contributing 21.5% to the total
intake. Other important sources were meat and meat products (chicken meat) and milk and dairy
products (yoghurt), with an estimated contribution of 20% and 15% to Zn intake, respectively (Table 6).
Top ten food sources of Zn in participants’ diets are presented in Figure 1.
Table 6. Contribution of different food groups to dietary Zn intake of study participants.
Food Group Average Zn Intake, Mg Contribution to Zn Intake, %
Grains and Grain Products 1.595 21.49
Meat and Meat Products 1.499 20.20
Milk and Dairy Products 1.104 14.88
Vegetables and Vegetable Products 0.888 11.97
Nuts, Seeds, and Kernels 0.789 10.63
Eggs and Egg Products 0.514 6.93
Fruit and Fruit Products 0.336 4.53
Non-Milk Beverages 0.314 4.23
Sugar and Sweets 0.141 1.90
Seafood and Related Products 0.152 2.05
Miscellaneous Food Products 0.081 1.09
Fat and Oil 0.008 0.11
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Figure 1. Top ten food sources of Zn in participants’ diets. 
The average daily dietary intakes of Fe and Cu were 9.6 mg and 1.4 mg per day, respectively. 
Dietary intake of Cu was inversely linked to delta 5 desaturase (AA:DGLA), r = −0.395, p = 0.04. 
Dietary intake of individual fatty acids has mainly not been correlated with their status. The 
exceptions were 20:3 n6 and 20:5 n-3. The link between the eicosapentaenoic acid (EPA; C20:5 n-3) 
status and intake was r = 0.384, p = 0.048. Intake of DGLA (20:3 n6) has been linked to the status of 
EPA, DPA, DHA inversely (r = −0.41, r = −0.21, r = 0.47; p < 0.05, respectively) and with adrenic acid 
(C22:4 n6) directly (r = 0.439, p = 0.03). 
4. Discussion 
This study reports on the trace elements levels in plasma (Zn, Cu and Fe), anthropometrical, 
biochemical and fatty acid status in a sample of dyslipidemic adult subjects residing in Serbia. It 
examines the link between dietary Zn intake and concentrations of minerals with lipid profile 
indicators, fatty acid composition, and desaturase enzyme activities. People with dyslipidemia have 
inadequate dietary intakes of Zn, low plasma Zn status, and an altered FA composition. The 
concentrations of plasma Zn were linked to BMI and obesity, and there was no correlation between 
the dietary Zn intake and plasma Zn status. The ability of the LA:DGLA ratio to respond to 
variations in dietary Zn intake is reconfirmed. Cu, along with Zn, may have a role in activity of 
desaturase enzymes. Mean plasma Zn concentration was 0.75mg/L. The percentage of people with 
low plasma Zn concentrations using the IZiNGs criteria was 30% (50% with levels below 0.75mg/L), 
which indicates the presence of Zn deficiency in this study population [53]. There were no subjects 
with plasma Zn levels under 0.5mg/L, most likely due to a proficient homeostatic regulation of Zn. 
Our findings are in line with Obeid et al. [56] who also demonstrated a risk of Zn deficiency in 
Lebanese subjects with metabolic syndrome. The low plasma Zn concentrations were also seen in 
obese individuals, those with hypertension and type 2 diabetes [57,58]. Fe and Cu status data were 
within the estimated reference ranges for adult population, and similar to the values reported 
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Figure 1. Top ten food sources of Zn in participants’ diets.
There was no correlation between the dietary Zn intake and plasma Zn status (p > 0.05). The dietary
Zn intake was inversely correlated with the LA:DGLA ratio (r = −0.38, p = 0.05), while there was no
significant relationship seen between the LA:DGLA ratio and dietary intake of Cu (r = −0.22, p = 0.26).
Dietary Zn intake did not correlate with ny of the biochemical or anthropometrical parameters
measure within this study ( ata not presented). No associations were found between the dietary
Zn intake and plasma status of individual FAs, except for the DGLA which was directly linked to the
dietary Zn intake (r = 0.47, p = 0.03).
The average daily dietary intakes of Fe and Cu were 9.6 mg and 1.4 mg per day, respectively.
Dietary intake of Cu was inversely linked to delta 5 desaturase (AA:DGLA), r = −0.395, p = 0.04.
Dietary intake of individual fatty acids has mainly not been correlated with their status. The exceptions
were 20:3 n6 and 20:5 n-3. The link between the eicosapentaenoic acid (EPA; C20:5 n-3) status and
intake was r = 0.384, p = 0.048. Intake of DGLA (20:3 n6) has been linked to the status of EPA, DPA,
DHA inversely (r = −0.41, r = −0.21, r = 0.47; p < 0.05, respectively) and with adrenic acid (C22:4 n6)
directly (r = 0.439, p = 0.03).
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4. Discussion
This study reports on the trace elements levels in plasma (Zn, Cu and Fe), anthropometrical,
biochemical and fatty acid status in a sample of dyslipidemic adult subjects residing in Serbia.
It examines the link between dietary Zn intake and concentrations of minerals with lipid profile
indicators, fatty acid composition, and desaturase enzyme activities. People with dyslipidemia
have inadequate dietary intakes of Zn, low plasma Zn status, and an altered FA composition.
The concentrations of plasma Zn were linked to BMI and obesity, and there was no correlation between
the dietary Zn intake and plasma Zn status. The ability of the LA:DGLA ratio to respond to variations
in dietary Zn intake is reconfirmed. Cu, along with Zn, may have a role in activity of desaturase
enzymes. Mean plasma Zn concentration was 0.75mg/L. The percentage of people with low plasma Zn
concentrations using the IZiNGs criteria was 30% (50% with levels below 0.75mg/L), which indicates
the presence of Zn deficiency in this study population [53]. There were no subjects with plasma Zn
levels under 0.5mg/L, most likely due to a proficient homeostatic regulation of Zn. Our findings
are in line with Obeid et al. [56] who also demonstrated a risk of Zn deficiency in Lebanese subjects
with metabolic syndrome. The low plasma Zn concentrations were also seen in obese individuals,
those with hypertension and type 2 diabetes [57,58]. Fe and Cu status data were within the estimated
reference ranges for adult population, and similar to the values reported elsewhere [33,59]. The highest
concentrations of Cu were seen in people with the lowest levels of plasma Zn. At the same time,
the lowest concentrations of plasma Fe were found in a group of people with the lowest plasma
Zn status. Decrease in serum Zn levels with a parallel increase in serum Cu concentrations has
previously been reported in patients with myocardial infraction [60] and metabolic syndrome [61].
Similarly, concomitant decreases in the concentrations of both Fe and Zn have been described in the
past [62,63]. No intercorrelations were seen between the concentrations of trace elements, which was
also in accordance with some previously reported data [64,65]. Serum Cu:Zn is a useful indicator for
identification of various diseases [66,67], including Zn deficiency [68]. Imbalances in the metabolism of
Zn and Cu predispose to dyslipidemia, increased arteriosclerosis and cardiovascular diseases [69,70].
The ratio of Cu:Zn is believed to be clinically more relevant than the individual concentrations of
either of these trace elements, and it is often used to show the general health state of an individual as
it is very easily affected by inflammatory conditions [71]. The optimal plasma Cu:Zn ratio is in the
range 0.7–1.00 [72] and the levels of 1.3 measured in this study certainly reflect a decreased nutritional
Zn status, but also an inflammatory response. The reduction in plasma Zn levels in this study group
could be explained by an increased uptake of Zn by tissues. Additionally, due to the presence of slight
inflammation there may be change in the protein Zn-binding capacities [73]. Furthermore, the plasma
Zn status did not correlate with dietary Zn intake, which is expected [33,74]. Sixty-five percent of our
study sample did not meet dietary Zn requirements, which certainly contributed to low plasma Zn
concentrations. Low dietary intake of Zn is found in people with a higher prevalence of coronary risk
factors [70]. The bioavailability of Zn from the diet is highly dependent on the phytate: Zn molar ratio,
and ratios above 15 are associated with a marked reduction in Zn absorption [53,75]. Dietary data are
showing that major sources of Zn in our study group are plant sources (cereals-white and wholemeal
bread), legumes and vegetables) with acknowledged high phytate content [76].
As majority of other databases, our database did not contain data on the amount of phytates in
selected foods, so the exact phytate: Zn molar ratio of consumed foods was not obtained. However,
when method by Jati et al. [77] was employed, Zn bioavailability from the diets consumed by our
participants fitted into the group of ‘high bioavailability’ where ≤ 50% of total energy intake is
accounted for from rice, other grains, other starchy staples, and pulses and nuts (35% in this group)
and >5% (7.5% in our study sample) of total energy intake is accounted for by protein from fish,
eggs, dairy, and meat. The association between anthropometric indicators and status of certain trace
elements in a dyslipidemic population has been investigated in the past [78,79]. As with earlier
findings [80,81] in our study no relationships were found between the statuses of trace elements
with age. The increasing concentration of plasma Zn was associated with higher BMI and weight,
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similar to previous reports [33,82,83]. Yu et al. [61] reported comparable results in metabolic syndrome
patients, higher serum Zn levels in those with higher weight. However, an inverse relation has also
been reported [79,84], and future studies in large dyslipidemic cohorts are needed to derive decisive
conclusions. Majority of our participants were either Zn deficient or with borderline Zn deficiency,
which might be in line with potential mechanistic background of the observed correlations. Zn is
an antioxidant, involved in the production of metalloenzymes and plays an important role in the
metabolism of fats [85]. Zn dependent alpha2-glycoprotein (ZAG) is an adipokine which stimulates
energy expenditure in skeletal muscle and brown adipose tissues resulting in reductions in body weight
and TGs [86]. Additional studies with more diverse dietary and/or plasma Zn statuses of participants
are needed to explore the causality of the associations observed herein. Similar to our study, previous
reports failed to demonstrate the relationship between serum Cu and Fe concentrations with cholesterol
and TG levels [17,82]. On the contrary, plasma Zn was directly and Cu:Zn ratio inversely associated
with LDL/HDL, Cho/HDL and non-HDL/HDL. Inconsistent data are reported in the literature, a direct
correlation between Zn and HDL [87,88] but also an inverse relationship [79,82]. An imbalance in
the metabolism of Cu has been linked to hypercholesterolemia and an increased Cu:Zn superoxide
dismutase was detected in obese individuals [89]. This obvious opposition between Zn and Cu has
been acknowledged in hypertension [90], type 2 diabetes [91] and elevated blood pressure [92]. Zn can
have an endogenous protective role against dyslipidemia and arteriosclerosis as it can inhibit the
oxidation of LDL-C and protect against inflammatory diseases by inhibiting the activation of oxidative
stress [82,93]. In our study, the insufficient dietary Zn intake and low plasma Zn concentrations could
alter the lipid status and contribute to development of dyslipidemia. The wider ranging studies are
now required to determine the exact order and underlying mechanisms of observed interactions further.
Little is known about the relation between the desaturase enzyme activities and common dyslipidemic
parameters. Increased ∆6 and ∆9 and reduced ∆5 desaturase activities are seen in people with chronic
diseases [28,61,94]. In accordance with the data from other studies [29,95,96] herein the ∆6 and ∆9
desaturase activities were directly linked to BMI. Finally, the LA:DGLA ratio was inversely associated
with BMI, Cho/HDL ratio and non-HDL/HDL and TG. The observed relations between the desaturases
and biochemistry related parameters may result from the alterations in the desaturases encoding genes
(FADS 1 and FADS2) that are linked to serum HDL-C and TG [97,98]. Moreover, desaturase enzymes
are coupled to the NAD (P) H-cytochrome b5 electron transferrin chain and insufficient dietary Zn
intake might affect the electron transferring chain and subsequently change the activities of desaturases
and their relationship with lipid status parameters [99]. Furthermore, Zn modifies cyclooxy-genase
activity and it acts as a co-enzyme for ∆6 desaturase [31–33,39]. The link between the ∆6 desaturase
and Zn has been studied both in animals and humans [32,34,35,39]. The LA:DGLA ratio has been
proposed as a potentially new biomarker of Zn status as it has been demonstrated that the ratio changes
in accordance to dietary Zn manipulations [32,33,39]. However, the sensitivity of this biomarker to
predict Zn status in Zn deficient human populations, as well as in people with an apparent presence of
inflammatory conditions has not been explored so far. In this study, an inverse relationship among the
LA:DGLA ratio and nutritional Zn status has been confirmed. Similarly, a noteworthy association
was observed between the LA:DGLA ratio and plasma levels of Cu. Cu is the third most abundant
essential trace element in the human body, and similarly to Zn, it also acts as a part of antioxidant
enzymes that protects against free radicals [100]. Zn and Cu are known as interacting metallic elements,
and an antagonistic relationship between Zn and Cu has been previously presented [89,101]. Herein,
the lower than recommended dietary intake of Zn possibly contributed development of Zn deficiency
and lead to a slightly misbalanced Cu:Zn ratio. The previously noted inverse trend between the
LA:DGLA ratio and dietary Zn intakes has been reconfirmed in this study, and the detected borderline
statistical significance was most likely due to the relatively uniform dietary Zn intakes of participants.
Demonstrated altered Cu:Zn ratio demonstrates that the balance of these minerals is disturbed to a
certain degree, in which situation Cu may be taking over Zn’s role, which is shown by a significant
relationship seen between the plasma Cu concentrations and the LA:DGLA ratio. Cu may have a
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unique effect on long-chain FA metabolism [30]. In the early 1971, Brenner & Catala proposed that Cu
can act on a metabolic pathway common to all FA desaturases, as a component of cupoprotein enzymes.
As with findings of this study, a positive correlation has been described, an increase in desaturase
activity with addition of Cu [102,103]. Active conversion of linoleic acid (LA) to its metabolites (GLA
and DGLA) depends on the levels of these trace elements, higher levels of Zn and lower levels of Cu
are an expected basis for an increased desaturase activity. It seems that Zn and Cu misbalance may be
an active modifier of the LA:DGLA activity in dyslipidemia; however, this should be confirmed by
further studies. The FA composition of serum phospholipids of this study group was similar to FA
statuses of patients reported in other studies, but the values for n-3 PUFAs were lower from the values
reported for healthy people [104–106]. The low intake and status of n-3 PUFA has been shown in obese
populations and those with metabolic syndrome [61]. Low levels of n-3 PUFA are known to decrease
the expression of mitochondrial messenger ribonucleic acid (RNA), which plays a role in a defense
against obesity [107]. The overconsumption of n-6 PUFA and a high ratio of n-6 to n-3 PUFA may add
to the increased obesity and dyslipidemia by stimulating low-grade chronic inflammation. N-3 PUFA
influences obesity through eicosanoid modulation leading to a decrease in inflammation [106,108].
As expected there was the highest concentration of omega-6 FAs that are known as ‘pro-inflammatory’
and the lowest amount of omega-3 FA ‘anti-inflammatory’ in participants’ diets. The idea of n-6
FAs as ‘harmful’ is starting to change [109]. New evidence is showing that high levels of LA are
inversely linked to the risk of development of cardiovascular diseases and mortality. The highest
blood levels of LA in addition to n-3 FA reduced a risk of death for more than 50% [109]. However,
the intake of n-3 FAs of participants in this group was below recommended intakes. In addition,
the concentration of adrenic acid (22:4 n-6) increased in this study group, when compared to other
reports in the literature [59,110]. 22:4 n-6 has a direct influence on the IKKb/NF-kB and inflammation
signaling [111] which can promote type 2 diabetes and obesity [112], so adequate concentrations of this
acid may be of great importance for prevention of obesity and dyslipidemia. Similarly, the n6/n3 PUFA
ratio in Western diets (projected to be 10–25:1) has increased together with the prevalence of obesity
and cardiovascular disease [113]. The reduction from 5:1 to 2:1 had a beneficial effect in preventing and
treating a chronic disease [114]. In this study group, the ratio of 12:1 was higher than recommended,
therefore achieving a much lower ratio may be beneficial for this dyslipidemic cohort. Very limited
information is available on the role of Cu, Zn and Fe in FA metabolism in a dyslipidemic population.
There were no statistically significant correlations between the plasma Zn and Fe with the statuses of
any of the FAs measured within this study. Cu:Zn ratio was not linked to the status of individual FAs,
while the plasma Cu was directly related to (alpha-linolenic acid (ALA,C18:3 n-3). Finally, it would
be beneficial to explore whether the examined associations remain after the improved dietary intake
of n-3 FAs and to what extend are potential dietary modifications able to diminish development of
dyslipidemia and related disorders. Palmitoleic acid (C16:1 n-7), a monounsaturated FA correlated
directly with BMI while oleic acid (C18:1 n-9) was linked to total cholesterol, which, if serum FA is
used as a surrogate indicator of the dietary intake of FA, means that there is an increased dietary
intake of monounsaturated FAs which contribute to increased cholesterol levels and obesity. This was
supported by the dietary intake data, saturated fats contributed 13% to the total energy intake, while
only 30% of fats consumed by this group was coming from PUFA sources. The direct correlation was
also observed between the dietary intakes of fats with weight related indicators, which is in accordance
with some previous reports [115,116]. Diets high in saturated fats and low in PUFAs may lead to the
development of dyslipidemia. To sum up, Zn deficiency (and altered Cu:Zn ratio) could be important
factors in decreased desaturase activity and modified FA metabolism. The obtained results should be
interpreted with caution as reverse interconnections cannot be totally excluded. Although conducted
within limited sample-size, our study results provide a valuable basis for further evaluation of the role
of important trace elements (Fe, Cu and Zn) in the development of dyslipidemia and related conditions.
The strengths of this study are the use of an entire range of independent biomarkers of dyslipidemic
status: serum FAs, plasma mineral concentrations, anthropometrical, biochemical, and dietary intake
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data. Blood levels of several individual FAs are investigated rather than FA groups. Limitations of the
present study include a lack of a directly measured inflammation indicators that could be assessed as
potential confounders to relations of interest and a surrogate measure of desaturase enzyme activities.
However, Cu:Zn ratio was used as an indicator for the presence of inflammation. Direct measurements
of desaturase activities are challenging for ethical reasons, so the method used to estimate desaturase
activity, the precursor-to-product ratio has frequently been used and has been shown to correlate well
with desaturase expression in human liver biopsies [117]. Method employed to validate bioavailability
of Zn is also generally accepted and often used in dietary data analysis. As far as we are aware, this
is the first study that documents plasma levels of Zn, Cu, and Fe in relation to an entire range of
anthropometrical, biochemical, FA status components, and desaturases activities in people suffering
from dyslipidemia. It was certainly the first study of this type in Serbia.
5. Conclusions
The results offered in the present study add novel information to the limited body of literature
on the relationship between the important trace elements (Zn, Cu and Fe) with fat intake and FA
metabolism in people with dyslipidemia. We showed that people with dyslipidemia have inadequate
dietary intakes of Zn and a low plasma Zn status. The increased Cu:Zn ratio indicates the presence of
a low-grade inflammatory conditions in this group. There were no correlations between the plasma Zn
and dietary Zn intake, and the increase in the concentration of plasma Zn was correlated with obesity.
Observed alterations in serum FA composition are most likely caused by Zn deficiency and an altered
Cu:Zn ratio. The inverse correlation between the dietary Zn intakes and the LA:DGLA ratio has been
reconfirmed. The LA:DGLA ratio was directly linked to plasma levels of Cu, which implies that Cu,
in addition to Zn, may have a role in activity of desaturase enzymes, particularly in Zn deficient people
and in those affected by inflammatory conditions. Dietary modifications related to the microelements
appear as suitable therapeutic strategies for people suffering from dyslipidemia, and further research
in the field is needed.
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